ОЗОН Фармацевтика Financial Statements (OZPH)

ОЗОН Фармацевтикаsmart-lab.ru %   2021 2022 2023   LTM ?
Report date 11.10.2024 11.10.2024 11.10.2024   26.11.2024
Currency RUB RUB RUB   RUB
Financial report URL  
Presentation URL  
Drug sales, bln pkg   308.6
Revenue, bln rub ? 17.7 19.0 19.7   24.3
Operating Income, bln rub 5.44 5.50 6.15   8.10
EBITDA, bln rub ? 6.04 7.19 7.54   9.14
Net profit, bln rub ? 3.95 3.65 4.00   4.83
OCF, bln rub ? 2.77 -0.994 4.66   6.76
CAPEX, bln rub ? 1.19 0.682 0.706   2.91
FCF, bln rub ? 1.26 -1.72 3.83   3.83
Dividend payout, bln rub   0.197
Dividend, rub/share ?   0.18
Ordinary share dividend yield, % 0.0% 0.0% 0.0%   0.6%
Dividend payout ratio, % 0% 0% 0%   4%
OPEX, bln rub 3.44 2.28 2.40   2.92
Cost of production, bln rub 8.86 9.48 10.8   12.7
Amortization, bln rub 0.6 0.7 0.9   1.0
R&D, bln rub   0.356
Employment expenses, bln rub 2.08 2.42 2.76  
Interest expenses, bln rub 0.570 1.000 0.883   1.24
Assets, bln rub 29.7 34.1 34.1   40.8
Net Assets, bln rub ? 12.8 14.7 17.1   22.9
Debt, bln rub 7.91 11.4 9.26   12.8
Cash, bln rub 1.37 1.11 0.950   2.67
Net debt, bln rub 6.53 10.3 8.31   10.1
Ordinary share price, rub 35.0 35.0 35.0   30.4
Number of ordinary shares, mln 1 000 1 000 1 000   1 099
Market cap, bln rub 35.0 35.0 35.0   33.3
EV, bln rub ? 41.5 45.3 43.3   43.4
Book value, bln rub 12.7 14.4 16.8   22.9
EPS, rub ? 3.95 3.65 4.00   4.40
FCF/share, rub 1.26 -1.72 3.83   3.49
BV/share, rub 12.7 14.4 16.8   20.9
EBITDA margin, % ? 34.2% 37.9% 38.2%   37.6%
Net margin, % ? 22.4% 19.3% 20.3%   19.9%
FCF yield, % ? 3.6% -4.9% 10.9%   11.5%
ROE, % ? 30.8% 24.9% 23.4%   21.1%
ROA, % ? 13.3% 10.7% 11.7%   11.9%
P/E ? 8.87 9.58 8.74   6.90
P/FCF 27.7 -20.4 9.14   8.70
P/S ? 1.98 1.85 1.77   1.37
P/BV ? 2.76 2.42 2.08   1.45
EV/EBITDA ? 6.88 6.29 5.75   4.75
Debt/EBITDA 1.08 1.43 1.10   1.10
Employees, people 1 958 2 112 1 982  
Labour productivity, mln rub/person/year 9.01 8.98 9.95  
Expenses per employee, thousand rub 1 060 1 145 1 391  
R&D/CAPEX, % 0.00% 0.00% 0.00%   12.22%
CAPEX/Revenue, % 7% 4% 4%   12%
ОЗОН Фармацевтика shareholders